Aandeel ISR ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen ISR Immune System Regulation Holding AB (publ)

Aandelen

ISR

SE0008212195

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Immune System Regulation AB Announces Sars-Cov-2 Dry Powder Nasal - Vaccine Booster Candidate, Isr52, Demonstrates Superior Immune Response, in Mouse Model Challenge Studies Compared to Subcutaneous injection of this vaccine
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022
ISR Immune System Regulation Holding AB Reports Earnings Results for the Half Year Ended June 30, 2022
ISR Receives Approval To Conduct Clinical Trial In Bangladesh
SARS-CoV-2 vaccine study approved by Bangladesh BMRC
ISR’s Immune System Regulation Holding AB Announces Sars-Cov-2 Vaccine Study Approved by Bangladesh Bmrc
ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.
ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to Scale-Up Its Spray-Dried Nasal Vaccine, Powder Formulation for Phase III
Delegation from Bangladesh visits ISR for study preparation
ISR Immune System Regulation : Holding Annual Report and Consolidated Accounts 2021 (eng) (PDF)
Redeye Initiates Coverage of ISR Holding
ISR - Immune System Regulation Holding AB (publ.) 2[nd] half of 2021, including year-end report is now published on the website: www.israb.se
ISR Immune System Regulation Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021
Iconovo : ISR to Test Inhalable, Nasal COVID-19 Vaccines in Bangladesh
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Half Year Ended June 30, 2021
Iconovo : receives an order for additional work from ISR for development of a nasal COVID-19 vaccine
BioStock: Iconovo and ISR develop new covid-19 inhalation vaccine
Iconovo : signs agreement with ISR for the development of inhaled covid-19 vaccine
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Full Year Ended December 31, 2020
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ISR
  4. Nieuws ISR Immune System Regulation Holding AB (publ)
  5. Andere talen